Tag
LENACAPAVIR
Gilead Sciences Inc. has announced a new licensing deal to provide its twice-yearly experimental HIV prevention drug, lenacapavir, to six generic drug manufacturers to produce affordable versions of the drug for 120 low- and middle-income countries, including Nigeria, once regulatory approval is secured.